- Home
- PCRX vs CVAC Comparison
PCRX vs CVAC Comparison
Compare PCRX & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCRX
- CVAC
- Stock Information
- Founded
- PCRX 2006
- CVAC 2000
- Country
- PCRX United States
- CVAC Germany
- Employees
- PCRX N/A
- CVAC N/A
- Industry
- PCRX Biotechnology: Pharmaceutical Preparations
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- PCRX Health Care
- CVAC Health Care
- Exchange
- PCRX Nasdaq
- CVAC Nasdaq
- Market Cap
- PCRX 1.2B
- CVAC 1.2B
- IPO Year
- PCRX 2011
- CVAC 2020
- Fundamental
- Price
- PCRX $21.85
- CVAC $5.27
- Analyst Decision
- PCRX Buy
- CVAC Hold
- Analyst Count
- PCRX 5
- CVAC 3
- Target Price
- PCRX $32.40
- CVAC $6.83
- AVG Volume (30 Days)
- PCRX 577.9K
- CVAC 520.0K
- Earning Date
- PCRX 11-06-2025
- CVAC 11-12-2025
- Dividend Yield
- PCRX N/A
- CVAC N/A
- EPS Growth
- PCRX N/A
- CVAC N/A
- EPS
- PCRX N/A
- CVAC 1.01
- Revenue
- PCRX $705,848,000.00
- CVAC $599,540,810.00
- Revenue This Year
- PCRX $7.27
- CVAC N/A
- Revenue Next Year
- PCRX $10.18
- CVAC $23.40
- P/E Ratio
- PCRX N/A
- CVAC $5.24
- Revenue Growth
- PCRX 2.25
- CVAC 675.15
- 52 Week Low
- PCRX $16.00
- CVAC $2.37
- 52 Week High
- PCRX $27.64
- CVAC $5.72
- Technical
- Relative Strength Index (RSI)
- PCRX 41.81
- CVAC 30.97
- Support Level
- PCRX $21.20
- CVAC $5.33
- Resistance Level
- PCRX $22.74
- CVAC $5.41
- Average True Range (ATR)
- PCRX 0.96
- CVAC 0.03
- MACD
- PCRX 0.14
- CVAC -0.01
- Stochastic Oscillator
- PCRX 59.08
- CVAC 0.00
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.